.png){kind=logo}
A wide range of ready-to-use models for your preclinical testing programs.
SYNGENEIC,IMMUNODEFICIENT, HUMANIZED MODELS
CDX, PDX, CANCER HUMAN CELLS
For over six decades, immunodeficient mouse models have have played a pivotal role in scientific research, providing a valuable platform for the engraftment of tumors or tissues from various species..
By integrating suitable genetic backgrounds, naturl mutations, and knock-in/knock-out genes, these immunodeficient models offer well-suited platforms for preclinical investigations in the field of oncology.
Our immunodeficient mice provide a versatile platform to study human tumors, including PDX, CDX, and IPCs. They allow for in vivo analysis of tumor, sensitivity/resistance to various therapies and efficacy studies of following drugs: chemotherapies, radiotherapies or combined therapies.
Janvier Labs is offering a wide range of well characterized immunodeficient models, by combining natural mutations, different genetic backgrounds and knock out models, giving then the opportunity to use our different models all along the preclinical programs, from the early to the most advanced stages of development.
The strategic combination of genetic backgrounds and genetic editing techniques results in immunodeficient models with varying degrees of immunodeficiency, offering powerful support for R&D programs aimed at advancing new innovative therapies.
Derived from academic research centres, humanized models generate more precise biological insight for translational research in immunotherapy.
These models are particularly useful for early phases of drug development during the preclinical trials.
The next generation of humanized models are improving the functionality of the reconstituted humain immune responses in mice.
At Janvier Labs, we develop and produce humanized mice, on the basis of NXG Human Immune System (HIS), by grafting our NXG immunodeficient mice with human cord blood CD34+ human cells afetre a busulfan or irridiation methodology in bone marrow depletion phase.
All mice are provided under the SOPF status with the engraftment follow up quality control that have been established to procure the best in line grafted models.
The NXG HIS has been already used for different preclinical studies.
Syngeneic mouse models, featuring a functional immune system that matches the genetic signature of the injected cancer cells, offer exceptional utility in evaluating the efficacy of immunotherapies.
Their contribution facilitated the development of today’s approved checkpoint inhibitors.
Xentech and JC Discovery® provide an opportunity to evaluate novel immune therapies using a specialized implantation methodology that mitigates tumor ulceration, a significant limitation typically encountered in these models.
The use of CDX tumor models prior to patient-derived xenograft (PDX) for the evaluation of new anticancer drugs is becoming the gold standard in preclinical oncology. Relevant models of breast cancers (TNBC, HR and HER2+ models), prostate cancers (AR-high, AR-low and NE models) and pediatric solid cancers have been developed for preclinical validation of several anticancer drugs that are now used in the clinic.
Human cancer cell lines remain a prevalent choice in laboratories for hit compound identification and serve as valuable tools for proof of concept studies subsequent to in vitro drug screening.
At JC Discovery® and Xentech, we provide the opportunity to conduct efficacy and PK/PD studies using your own xenograft cell lines on immunodeficient mice ( such as athymic nude, SCID, NXG, etc.) or with any commercially available cell lines, enabling drug evaluation within the same model used in vitro.
Additionally, our well-characterized humanized mice (CD34+ hematopoietic stem cell-engrafted NXG or human PBMC injected NXG) allow for tailored pilot studies based on your specific needs.
.
Despite considerable progress in understanding the biology of cancer in humans, the development of effective therapies is hampered by the lack of sufficient experimental models that recapitulate the cancer genetic diversity. The use of patient-derived xenograft (PDX) for the evaluation of new anticancer drugs is becoming the gold standard in preclinical oncology. The faithful reproduction of patients’ cancer features, and the possibility to generate a large number of models that recapitulate patient population genetic heterogeneity, confer PDXs a critical added value in the evaluation of new candidate drugs. Over the last 15 years, we have generated and characterized a collection of 200+ PDXs from different solid tumors that accurately reproduce the histological and molecular heterogeneity of the tumors of origin.
Our extensive repertoire includes highly relevant models of breast cancers (such as TNBC, HR and HER2+ models), prostate cancers (AR-high, AR-low and NE models), and pediatric solid cancers (part of ITCC-P4 consortium). These comprehensive panels serve as invaluable preclinical tools for your drug development.
Thus, they have enabled the preclinical validation of several anti-cancer drugs that are now used in the clinic.
For immune therapies evaluation studies can be performed on humanized mice (CD34+ hematopoietic stem cell-engrafted NXG or human PBMC injected) – pilot studies can be led on demand.
Additionally, our well-characterized humanized mice (CD34+ hematopoietic stem cell-engrafted NXG or human PBMC injected NXG) allow for tailored pilot studies based on your specific needs.
We aim at accelerating the selection of lead T-cell products (CAR-T and therapeutic T-cells) and models for clinical translation by
We intervene on the "target validation" segment of the discovery process via the design of new preclinical models with high predictive value for clinical safety and efficacy.
Advanced, proprietary preclinical mouse models for the understanding of the molecular and cellular basis of human diseases with an emphasis on immuno-oncology and inflammation.
THERAPEUTIC AREAS: Immunology, Immuno-oncology, Dermatology (skin inflammatory disorders), Infectiology, Inflammation, Sepsis, Metabolism (NASH), IgG4-related diseases, Neurology, Rare diseases
What's the timeline for model generation?
The estimated timeline depends on the desired genetic modification, careful evaluation of the target gene locus and technology used, CRISPR-Cas9 or homologous recombination. From project initiation to F1 generation and genetic validation, it takes between 16 and 44 weeks. We take care of securing your strain before ensuring the customized breeding providing you with strandardized cohorts and supporting your research projects within the competitive timeframe.
Can I make a model with complex multitask alleles?
Our team of mouse geneticists has a longstanding experience and will guide you to carefully evaluate the feasibility of the desired gene editing to achieve complex multitask alleles.
What is the technical and economical feasibility for the creation of my model?
A dedicated team of mouse geneticists experts will work with you to design a model that will technically achieve your research needs and economical options. They use wide variety of model generation technologies and can advise on which strategies will minimize risk. It will take 2 weeks in average depending on the complexity of the model to be designed.
Do I have an intellectual property of model I order?
Regardless of the technique used to create your model, by homologous recombination or by CRISPR-Cas9 gene editing, the newly created model belongs to you. The model characterization data provided by our experts at JC Discovery® are also covered by our intellectual proprietary rights.
.svg)
.svg)